it has not received MHRA or EMA approval
Retatrutide is a triple-receptor agonist that activates GLP-1, GIP, and glucagon pathways simultaneously, making it the most potent injectable weight loss compound currently in advanced clinical development
This change in normal digestive rhythm, combined with dietary modifications and activation of GLP-1 receptors in the intestinal lining, can lead to changes in bowel habits including diarrhea in some patients
Those are the top three nutritional advice pieces for someone starting on a GLP-1
They ran some more tests afterward and told me I had costochondritis
This slowing of digestion, while beneficial for weight loss, can also lead to nausea, especially during the initial phase of treatment